CARSON CITY, Nev., Oct. 26, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that clinical safety data from the Company's Phase 2 open-label study evaluating the efficacy and safety of BIV201, terlipressin administered as a continuous infusion, in patients with refractory ascites due to cirrhosis, will be highlighted in a late-breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2023, taking place from November 10-14, 2023 in Boston, MA.
The abstract titled "Safety and Tolerability of Continuous Infusion Terlipressin (Biv201) In Patients with Decompensated Cirrhosis and Refractory Ascites: A Phase 2, Randomized, Controlled, Open-Label Study" will be presented by Penelope Markham, Ph.D., BioVie's Senior Vice President of Ascites and Strategic Initiatives on Monday November 13 from 1:00 PM – 2:00 PM.
Details of the presented data and conclusions will be announced once the presentations are made public at the conference.
About BioVie
BioVie Inc. (NASDAQ:BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and ...